D-1278-2019 Class III Terminated
FDA drug recall D-1278-2019 was initiated by Pfizer Inc. on Apr 29, 2019 and is designated Class III. Reason for recall: Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg… The recall status is terminated (terminated Apr 26, 2021). Affected quantity: 100277 tablets.
Recall details
- Product Type
- Drugs
- Report Date
- May 22, 2019
- Initiation Date
- Apr 29, 2019
- Termination Date
- Apr 26, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 100277 tablets
Product description
Relpax (eletriptan HBr) 40 mg, a) 12 tablets 2 cards x six 40 mg tablets per blister pack, NDC 0049-2340-05; b) 6 tablets 1 card x six 40 mg tablets per blister pack, NDC 0049-2340-45, Rx Only, Made in Ireland, Distributed by Roerig, Division of Pfizer Inc, NY NY 10017.
Reason for recall
Labeling: Label Error on Declared Strength: an artwork error on the secondary packaging of Relpax 40 mg Tablets, indicates that each tablet contains eletriptan hydrobromide equivalent to 20mg eletriptan, instead of 40mg, on one side of the carton.
Distribution pattern
Nationwide in the USA
Code information
Lot #s: a) W38322, Exp 10/2020, W98482, Exp 03/2021; b) W64062, Exp 01/2021, X27517, Exp 03/2021, AJ3674, Exp 11/2021.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1278-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026